#USA #New York #Class Action #Securities Fraud #BioAge Labs

Class Action Lawsuit Against BioAge Labs, Inc.

On January 31, 2025, Levi & Korsinsky, LLP announced a class action securities lawsuit against BioAge Labs, Inc. (NASDAQ: BIOA), pertinent to investors who suffered losses due to alleged securities fraud. This class action seeks to represent investors who purchased shares linked to BioAge’s initial public offering (IPO) on or about September 26, 2024.

Overview of the Case

The grievance involves shareholders adversely affected by significant disclosures made by BioAge. Specifically, on December 6, 2024, the company revealed the discontinuation of its STRIDES Phase 2 trial for azelaprag, which is its lead product candidate. The halt was attributed to safety issues concerning elevated liver transaminase levels among participants, a revelation that took many investors by surprise since the company had previously highlighted azelaprag’s promising prospects just months earlier during its IPO.

Following this announcement, the valuation of BioAge's shares plummeted from $20.09 to $4.65 in just a single day. This dramatic decline in stock prices has prompted investors to consider their options and pursue legal recourse for damages incurred.

Who Can Participate?

If you are an investor who experienced a financial loss linked to your investment in BioAge within the relevant time frame surrounding the IPO and the subsequent announcement, now is the time to act. You have until March 10, 2025, to file a request with the Court to be designated as a lead plaintiff. It’s important to note that you are not required to take on this lead role to benefit from any financial recovery; participation is not contingent upon you being a lead plaintiff.

No Financial Burden to You

Engaging in this class action suit comes at no cost to you if you qualify as a member of the class. There are no upfront fees or expenses associated with your participation. Levi & Korsinsky’s commitment is evident; the firm has a proven track record of securing compensation for investors in similar cases. They have successfully represented clients seeing hundreds of millions of dollars in recoveries across various high-stakes litigation.

Why Levi & Korsinsky?

With over 20 years of experience in the field and a dedicated team of more than 70 professionals, Levi & Korsinsky stands as one of the leading firms in securities litigation. For seven consecutive years, they have made the ISS Securities Class Action Services' Top 50 Report as one of the premier securities litigation firms in the United States. Their reputation speaks volumes, making them an excellent choice for investors seeking representation in this class action.

How to Proceed

Eligible investors wanting to explore their options can reach out to Joseph E. Levi, Esq., at [email protected] or by calling (212) 363-7500 for further information.

For more details on the class action and specific steps you may need to undertake, visit Levi & Korsinsky's website.

In summary, BioAge Labs presents a notable case of corporate accountability and investor rights. Keep an eye on the deadlines and make sure your voice is heard within this significant class action lawsuit.

Conclusion

This situation with BioAge serves as a stark reminder of how quickly market dynamics can shift and the importance of being informed as an investor. Those affected by the situation at BioAge Labs have an opportunity to regain some of their losses through this legal action, and should act promptly before the March 10 deadline approaches.